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Abstract.  The tissue-specific homing of lymphocytes 
is directed by specialized high endothelial venules 
(HEV). At least three functionally independent lym- 
phocyte/HEV recognition systems exist, controlling the 
extravasation of circulating lymphocytes into periph- 
eral lymph nodes, mucosal lymphoid tissues (Peyer's 
patches or appendix), and the synovium of inflamed 
joints. We report here that antibodies capable of in- 
hibiting human lymphocyte binding to one or more 
HEV types recognize a common 85-95-kD lympho- 
cyte surface glycoprotein antigen, defined by the non- 
blocking monoclonal antibody, Hermes-1. We demon- 
strate that MEL-14, a monoclonal antibody against 
putative lymph node "homing receptors" in the mouse, 
functionally inhibits human lymphocyte binding to 
lymph node HEV but not to mucosal or synovial 
HEV,  and cross-reacts with the 85-95-kD Hermes-1 
antigen. Furthermore, we show that Hermes-3, a novel 
antibody produced by immunization with Hermes-1 
antigen isolated from a mucosal HEV-specific cell line, 
selectively blocks lymphocyte binding to mucosal 
HEV.  Such tissue specificity of inhibition suggests that 
MEL-14  and Hermes-3 block the function of specific 
lymphocyte recognition elements for lymph node and 
mucosal HEV,  respectively. Recognition of synovial 
HEV also involves  the 85-95-kD Hermes-1 antigen, in 
that a polyclonal antiserum produced against the iso- 
lated antigen blocks all three classes of lymphocyte- 
HEV interaction. From these studies, it is likely that 
the Hermes-l-defined 85-95-kD glycoprotein class ei- 
ther comprises a family of related but functionally in- 
dependent receptors for HEV,  or associates both physi- 
cally and functionally with such receptors. The find- 
ings imply that related molecular mechanisms are in- 
volved in several functionally independent cell-cell 
recognition events that direct lymphocyte traffic. 
S 
PECIFIC heterotypic cell-cell associations  are an es- 
sential feature in the development and function of com- 
plex biological systems. In general, however, the mo- 
lecular basis of such interactions remains a mystery. Models 
based on cell type-specific recognition elements or receptor/ 
ligand systems, such as the chemoaffinity hypothesis for the 
development of neural connections (Sperry,  1965), have re- 
cently been replaced in part by the concept that cellular con- 
nections may be determined by the temporal  and  spatial 
regulation of relatively nonspecific cell adhesion molecules 
(Edelman, 1983). One system in which cell type-specific rec- 
ognition does operate is the interaction of lymphocytes with 
high endothelial venules (HEV, 1 venules specialized to sup- 
port the extravasation of circulating  lymphocytes from the 
blood). Lymphocyte-HEV  interactions exhibit a remarkable 
tissue specificity: Functional in vivo and in vitro studies have 
revealed the existence of at least three independent lympho- 
1.  Abbreviations  used in  this paper:  ALS, antilymphocyte serum;  HEV, 
high endothelial venule; PBL, peripheral blood lymphocyte. 
cyte-endothelial cell recognition  systems, controlling  lym- 
phocyte extravasation  in peripheral  lymph nodes,  in  the 
mucosal lymphoid organs (Peyer's patches or appendix), and 
in inflamed synovium (Butcher et al.,  1980; Stevens et al., 
1982; Chin et al., 1984; Jalkanen et al., 1986c). As assessed 
in an in vitro assay of lymphocyte  binding to HEV in frozen 
sections (Stamper and Woodruff, 1976; Butcher et al., 1979; 
Jalkanen and Butcher,  1985), many normal small B and T 
lymphocytes are apparently  able to interact with all three 
HEV classes (Stevens et al., 1982), but certain transformed 
or neoplastic lymphoid lines as well as some differentiated 
effector cell populations display exquisite specificity for par- 
ticular organ HEV (reviewed in Jalkanen et al., 1986b; Butch- 
er,  1986; Gallatin et al.,  1986). These organ-specific  lym- 
phocyte-HEV interactions control the migration and tissue 
distribution of lymphocyte subsets, and are thought to play 
a key role in determining the characteristics of local immune 
responses. 
Our laboratory has undertaken to identify and characterize 
molecules involved  in  lymphocyte recognition  of lymph 
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previously isolated a monoclonal antibody, Hermes-l, that 
defines 85-95-kD human lymphocyte surface glycoproteins 
involved in lymphocyte binding to lymph node HEV (Jalka- 
nen et  al.,  1986a).  Because Hermes-1  does not interfere 
directly  with  the  binding  event,  the  importance  of  the 
Hermes-1  antigen in lymphocyte adherence to lymph node 
HEV was inferred from three principal observations: (a) ex- 
pression of the antigen on normal and transformed human 
lymphocyte populations is correlated with their HEV-bind- 
ing  ability;  (b)  fluorescence-activated cell  sorter-selected 
Hermes-1 h~ variants of a  cloned cell line display increased 
HEV-binding ability; and (c) the affinity-isolated Hermes-1 
antigen absorbs antibodies that are capable of blocking lym- 
phocyte-lymph node HEV binding from heterologous rat 
anti-human lymphocyte sera. These studies provided con- 
vincing evidence of the involvement of the Hermes-1  antigen 
in lymphocyte binding to lymph node HEV, but they did not 
address the role of this antigen in the organ specificity of 
HEV recognition. Nor did they address the molecular mech- 
anisms of lymphocyte binding to mucosal or synovial HEV. 
In the studies reported here, we describe monoclonal anti- 
bodies that selectively inhibit lymphocyte binding to lymph 
node or to mucosal HEV, and demonstrate that these block- 
ing antibodies recognize the  Hermes-l-defined 85-95-kD 
glycoprotein class ("gp90").  Furthermore, we show that an 
anti-gp90 serum blocks lymphocyte binding to lymph node, 
mucosal,  and synovial HEV.  The results  suggest that the 
Hermes-l-defined gp90 either comprises a family of antigen- 
ically and structurally related receptors for HEV,  or is as- 
sociated both physically and functionally with lymphocyte 
surface molecules responsible for HEV recognition. 
Material and Methods 
Cells 
Human peripheral blood lymphocytes (PBL) were isolated using Ficoll- 
Hypaque (Histopaque-1077,  Sigma Chemical Co.,  St.  Louis,  MO).  Cell 
lines were a girl of E. Engleman (IBW4, KCA), and Dr. H. Kaplan (LB25) 
of Stanford University. 
In Vitro HEV Assay 
The in vitro assay of  lymphocyte binding to HEV in frozen sections has been 
described (Jalkanen and Butcher,  1985). Briefly,  sample lymphocytes in 
RPMI 1640 containing 5 % fetal calf serum and 20 mM Hepes, pH 7.3, were 
incubated with mild rotation for 30 min at 7°C on freshly cut frozen sections 
of human peripheral lymph nodes, appendix, or inflamed synovium, or 
mouse peripheral nodes or Peyer's patches. (Similar results are obtained on 
mouse and human HEV [Wu,  N., S. Jalkanen, and E. C. Butcher, manu- 
script in preparation].) Synovium, from patients with either rheumatoid ar- 
thritis or the  inflammatory arthritis associated with Lyme disease, was 
generously provided by A. Steere and R. Fox. Assays were carried out at 
a cell density (2  ×  107/ml) well below that required for saturation of HEV 
(i.e., at a density known to yield linear increases in HEV-bound cells with 
increases in cell number [Jalkanen and Butcher, 1985]).  After incubation, 
adherent cells were fixed in cold PBS containing 1% glutaraldehyde, and 
cell binding was quantitated microscopically as described in Jalkanen and 
Butcher (1985) and in the figure legends. Results are presented as relative 
adherence ratios, the calculated number of sample cells bound to HEV per 
reference (control antibody-treated or untreated) cell binding under identi- 
cal conditions (see figure legends). Standard errors were determined by the 
delta method (Rao,  1965). 
Labeling and Immunoprecipitation 
Human  PBL  were  iodinated  with  ~25I (New  England  Nuclear,  Boston, 
MA) by the lactoperoxidase method as described (Jalkanen et al., 1986a). 
Iodinated cells were lysed with 2  ml/107 cells lysis buffer (0.1 M  NaCI, 
0.01 M sodium phosphate, 1% Triton X-100, 0.5 % deoxycholate, 0.1% SDS, 
and 1% aprotinin, pH 7.4),  and the lysate was clarified by centrifugation at 
10,000 g for 15 min. For the analyses of the MEL-14 antigen presented in 
Fig. 2,500-gl aliquots were precleared two times for 4 h at 4°C with 25 
lal of cyanogen bromide-Sepharose 4B beads coupled with normal rat se- 
rum, and immunoprecipitation was carried out with Sepharose 4B beads 
conjugated with Hermes-l, MEL-14, or the control antibody 30G12. All an- 
tibodies were conjugated at 5 mg/ml of packed Sepharose beads. To deter- 
mine whether the MEL-14 antigen on PBL was also recognized by Hermes- 
1,  one aliquot  was precleared with Hermes-1  two times with  12  gl  of 
Hermes-l-Sepharose beads for 5-12  h at 4°C before immunoprecipitation 
with MEL-14. 
For the analyses with Hermes-3 and with the anti-gp90 serum presented 
in  Figs.  4  and  6,  200-gl  aliquots  of lysate,  prepared as  above,  were 
precleared four times with 12 ~tl of protein A-Sepharose (Pharmacia Fine 
Chemicals, Piscataway,  NJ)  bearing roughly 5  Ixg of rabbit anti-mouse 
(Sigma Chemical Co.) or anti-rat (Calbiochem Behring Corp., San Diego, 
CA) Ig, and saturating levels of either normal mouse serum or the control 
monoclonal antibodies indicated in the figure legends. Specific immunopre- 
cipitation was carried out with 12 I.tl of protein A-Sepharose beads, armed 
with anti-mouse Ig and Hermes-3 or anti-gp90, or with anti-rat lg and 
Hermes-1. 
For SDS-PAGE, the beads were washed four times in lysis buffer, the ra- 
diolabeled antigen was eluted by boiling 3 min in 50 ~tl of Laemmli sample 
buffer (Laemmli, 1970), and the immunoprecipitate was analyzed by SDS- 
PAGE (9% polyacrylamide) under reducing conditions. Molecular weight 
standards were myosin, 205,000;  13-galactosidase,  116,000; phosphorylase 
B, 94,700;  bovine serum albumin, 66,000;  egg albumin, 45,000;  and car- 
bonic anhydrase, 29,000. 
Monoclonal A n tibodies 
Production and characterization of Hermes-1 (Jalkanen et al.,  1986a) and 
MEL-14 (Gallatin et al.,  1983) have been described. Both are rat IgG2~ 
antibodies. 
Hermes-3, a mouse IgG2a, was produced by immunization of BALB/c 
mice with purified Hermes-1 antigen from KCA, a human B lymphoblastoid 
line that binds preferentially to mucosal HEV.  7  ×  l0  w KCA cells were 
lysed in 3.5 liters of lysis buffer (2% Triton X-100, 0.15 M  NaC1, 0.01 M 
Tris,  1.5 mM MgC12, 1 mM PMSF, and 1% aprotinin), and the clarified 
lysate was adjusted to pH 5.8 with HCI and applied to a DEAE-Sepharose- 
6B column (Pharmacia Fine Chemicals). The bound acidic proteins were 
eluted with 0.8 M NaCI at pH 5.2.  The effluent was diluted to isotonicity 
with deionized water, adjusted to pH 7, and applied sequentially to three 
Sepharose 4B columns, derivatized respectively with normal rat  serum, 
with an irrelevant monoclonal antibody (L3B12),  and with Hermes-1 (5 
mg/ml, 3 mi column volume). The material bound to the Hermes-1 column 
was elnted with 50 mM triethanolamine and lyophilized. The affinity bind- 
ing and subsequent steps were repeated twice. The resulting antigen prepa- 
ration  contained Hermes-1  antigen  (roughly  80%  as assessed by  SDS- 
PAGE) admixed with lesser amounts of contaminating antibody from the 
affinity column. BALB/c mice were immunized three times during a 6-8-wk 
period with the affinity-purified Hermes-1 antigen in complete Freund's ad- 
juvant (x 1) or incomplete Freund's adjuvant (subsequently) intraperitoneal- 
ly, followed by a final intrasplenic injection of the purified antigen in saline. 
The spleen cells were fused (Kohler and Milstein, 1975) 3 d later with Sp2/0 
(Schulman et al., 1978) mouse myeloma cells. Hybrid clones were selected 
in  hypoxanthine-aminoptherin-thymidine medium,  and  supernatants that 
stained PBL in an immunofluorescence assay were screened by analyzing 
their blocking activity in the in vitro HEV assay. The Hermes-3-secreting 
hybrid was subcloned two times by limiting dilution. 
Rat IgG2a control antibodies included 30G12,  specific for the mouse 
lymphocyte antigen T200,  a  generous gift of J.  Ledbetter (Ledbetter and 
Herzenberg,  1979); and 281-2,  against murine epithelial cell surface pro- 
teoglycan, a gift of M. Jalkanen (Jalkanen et al.,  1985). 
Antisera 
A  polyclonal mouse antiserum against the Hermes-1 antigen (anti-gp90) 
was obtained from mice hyperimmunized with the purified antigen, isolated 
and prepared as described above under the discussion of Hermes-3. 
A hyperimmune rat antiserum against human lymphocytes (antilympho- 
cyte serum, ALS) was produced by repeated immunization with whole hu- 
man peripheral blood and tonsillar lymphocytes, as described (Jalkanen et 
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surface-bound polyclonal antibodies on PBL binding to HEV (see Fig. 7), 
the ALS was absorbed with isolated Hermes-1 antigen to remove antibodies 
reactive with the gp90 class; 400-~tl  aliquots were incubated with 200 ~tl 
of Hermes-l-conjugated Sepharose beads bearing adsorbed gp90 (Hermes-1 
antigen) from the lysate of '~2  ×  10  s tonsil cells. 
Immunofluorescence Cell Staining 
Single-color indirect immunottuorescence was  carried  out  as  described 
(Jalkanen et al., 1986a) using saturating levels of first-stage antibodies fol- 
lowed by the appropriate second-stage reagent, either FITC-goat anti-rat 
IgG  (Sigma Chemical  Co.)  or FITC-sheep anti-mouse IgG (Fab2  frag- 
ments, Sigma Chemical Co.). Negative control staining was carried out with 
a mixture of the two second stages. 
Results 
A gp90 Involved in Lymphocyte Recognition 
of  Lymph Node HEV 
Lymphocyte interactions with HEV can be studied in a sim- 
ple in vitro system in which lymphocytes adhere selectively 
to HEV when incubated on fresh frozen sections of lymph 
Figure 2. MEL-14 immunoprecipitates  a 90-kD species that is also 
recognized by Hermes-1.  Lysates  of surface-iodinated  PBL were 
precipitated  with: lane A, Hermes-l; lane B, negative control anti- 
body 30G12; lane C, MEL-14; lane D, MEL-14 after preclearing 
two times  with Hermes-1.  The MEL-14 precipitate  is removed by 
preclearing with Hermes-1. 
Figure 1. MEL-14 inhibits lymphocyte binding to lymph node HEV, 
but not to HEV in mucosal lymphoid tissues (appendix and Peyer's 
patches) or inflamed synovium. The inhibitory effect of MEL-14 on 
the HEV binding of PBL (shaded bars) and of the cloned B lym- 
phoblastoid line IBW4 (hatched bars) was assessed  as previously 
described (Jalkanen  et al.,  1986c).  Sample cells  (either  PBL or 
IBW4 cells,  2  x  107 per sample)  were incubated  with 180 ~tg of 
purified  MEL-14 or of the control antibody 30G12 for 1 h and the 
antibodies  were included during the assay. The same number of 
MEL-14-treated or control cells were incubated in parallel on serial 
frozen sections  of peripheral  lymph nodes,  Peyer's patches  or ap- 
pendix, and synovium. The average number of MEL-14 treated cells 
bound per HEV was determined microscopically,  and was divided 
by the  average  number of control cells  per  HEV,  as described 
(Jalkanen  and Butcher,  1985), to yield a relative  adherence ratio. 
The adherence of control antibody-treated  cells  (lymphocytes or 
IBW4 cells) defines a relative adherence ratio of unity on each HEV 
class (dotted line). The relative  adherence ratios,  presented  with 
standard errors, represent  data pooled from three experiments  with 
similar results (one on mouse lymph nodes and Peyer's patches,  and 
two on human lymph nodes and appendix;  synovial tissue was al- 
ways human). 
nodes or other tissues (Stamper and Woodruff, 1976; Butcher 
et al.,  1979; Jalkanen and Butcher, 1985). By using this assay 
system,  we  have  now  observed  that  monoclonal antibody 
MEL-14, originally selected as recognizing putative mouse 
lymph node homing receptors (Gallatin et al.,  1983), cross- 
reacts in a  functionally significant manner with the human 
Hermes-1  antigen.  As reported previously (Jalkanen et al., 
1986c) and confirmed in additional experiments here, MEL- 
14 inhibits the binding of human PBL to lymph node HEV, 
but not to mucosal or to synovial HEV (see Fig.  1, shaded 
bars). The interpretation that this inhibition is due to block- 
ade of a specific lymphocyte receptor (and not to nonspecific 
toxic effects or membrane alterations) assumes that many or 
all  individual  lymphocytes express  receptors  for all  HEV 
types.  Although  this  assumption  is  supported  by  murine 
studies (Stevens et al.,  1982), it remained formally possible 
that MEL-14 was simply toxic to cells bearing its cognate an- 
tigen, and that most or all PBL binding to mucosal and syno- 
vial HEV were MEL-14- and therefore uneffected. MEL-14 
stains  human lymphocytes only weakly in immunofluores- 
cence assays, presumably because its cross-reactivity with 
the human antigen represents a relatively low avidity interac- 
tion;  thus  it  has  not  been  technically  feasible  to  assess 
directly the expression of the MEL- 14 antigen by PBL bound 
to mucosal or synovial HEV. Therefore, we tested the effect 
of MEL-14  on  a  cloned,  homogeneous  human  cell  line, 
IBW4, that is capable of binding to both lymph node and to 
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(hatched bars), MEL-14 also blocked the binding of IBW4 
in an organ-specific fashion.  This specificity of inhibition 
suggests,  as  argued in the mouse studies  (Gallatin et al., 
1983), that the effect of MEL-14 cannot be due to nonspecific 
alterations in lymphocyte function, but rather that the MEL- 
14 antigen either functions as a specific receptor for lymph 
node HEV, or enjoys a close physical association with the ac- 
tual recognition elements. 
As shown in Fig. 2, MEL-14 immunoprecipitates a 90-kD 
band from lysates of surface iodinated human PBL, and this 
MEL-14 antigen is precleared by absorption with Hermes-1. 
Thus both the Hermes-l- and MEL-14-defined epitopes are 
present on human lymphocyte surface glycoproteins (gp90) 
involved in recognition and binding to lymph node HEV. 
Recognition of  Mucosal HEV  AIso Involves 
the Hermes-I-defined gp90 
We next wished to identify elements involved in recognition 
of  mucosal HEV. Our approach was based on the observation 
that  antibody  Hermes-1  binds  in  high  levels  not  only to 
lymph node HEV-specific cells, but also to the B lympho- 
blastoid line KCA,  which interacts preferentially with mu- 
cosal HEV. (KCA ceils bind 0.6-1.0 times as well as PBL to 
appendix or Peyer's patch HEV, but essentially at background 
levels, ~<0.05 times as well as PBL, to HEV in lymph nodes 
or in  inflamed synovium [Jalkanen et al.,  1986a;c].)  One 
possible explanation for the staining of KCA with Hermes-1 
was that molecules involved in recognition of mucosal HEV 
also  bear  the  Hermes-1  epitope.  With  this  possibility  in 
Figure 3. Effect of Hermes-3 on PBL binding to HEV. PBL were 
preincubatexl with  600  ~tl of hybridoma  supernatant containing 
Hermes-3 for 1 h, and were then applied to frozen sections in the 
standard HEV-binding assay. Negative control  incubations were 
carried out either with Hermes-l-containing supernatant (Hermes-1 
does not alter the HEV-binding ability of lymphocytes), or with hy- 
bridoma supernatant without known reactivity. Binding was quanti- 
tated as for Fig. 1. The relative adherence ratios presented with stan- 
dard errors, represent pooled data of three experiments with similar 
results (one using human lymph nodes and appendix, and two using 
mouse lymph nodes and Peyer's patches). The binding of control- 
treated lymphocytes defines relative adherence ratio of  unity (dotted 
line). 
Figure 4. Immunoprecipitation studies with Hermes-3. Lysates of 
iodinated PBL were precipitated with Hermes-3 (lanes .4 and B) or 
Hermes-1 (C and  D)  after preclearing  with  control  rat  IgG2a 
(30G12, lanes .4 and C), with Hermes-1 (lane B) or with Hermes-3 
(lane D).  Lane E, negative control precipitation with a rat IgG2a 
control antibody, 281-2. The Hermes-3 immunoprecipitate (lane A) 
is completely absorbed by Hermes-1 (lane B); and conversely, the 
Hermes-1 precipitate  (lane  C)  is  removed by  absorption  with 
Hermes-3 (lane D). 
mind,  the Hermes-1  antigen was purified by ion exchange 
and affinity chromatography from lysates of KCA, and the 
isolated antigen was used to immunize mice for the produc- 
tion of monoclonal antibodies. Antibodies were selected ini- 
tially for their ability to stain PBL in indirect immunofluores- 
cence studies, and were subsequently tested for inhibition of 
lymphocyte-HEV binding in the in vitro assay. 
One antibody, Hermes-3, inhibited the binding of PBL to 
mucosal HEV (Fig. 3). Furthermore, even though Hermes-3 
stained nearly all PBL (and therefore was not interacting ex- 
clusively with a mucosal HEV-specific lymphocyte subset; 
cf. Fig. 5), the antibody was without effect on lymphocyte 
binding to lymph node or synovial HEV.  Thus,  as argued 
above for MEL-14,  the inhibition by Hermes-3 cannot be 
secondary to nonspecific membrane or cellular effects.  Im- 
munoprecipitation analyses confirm, as predicted from the 
immunogen used,  that Hermes-3 recognizes an 85-95-kD 
species. As shown in Fig. 4 (lanes A and B), preclearing ex- 
periments demonstrate that  the  Hermes-3-defined protein 
bears the Hermes-1 epitope. It is intriguing that Hermes-3 is 
in fact able to preclear the entire gp90 class recognized by 
Hermes-1 (Fig. 4, lane D). In addition, as shown in Fig. 5, 
B  and  C,  Hermes-3 stains intensely not only the mucosal 
HEV-specific cell line KCA, but also the lymph node HEV- 
specific line LB25. (LB-25 binds '~70%  as well as PBL to 
lymph node HEV, but essentially at background levels to 
HEV in mucosal lymphoid tissues or in synoviurn [Jalkanen 
et  al.,  1986a,c].)  These  findings  suggest  that  Hermes-3 
recognizes gp90 involved, directly or indirectly, in recogni- 
tion both of lymph node and of mucosal HEV, but that anti- 
body binding to the Hermes-3 epitope interferes selectively 
with the mucosal HEV-binding activity (presumably steri- 
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rues-3. The three panels illustrate the similarity of Hermes-1 (solid 
line) and Hermes-3 (dashed  line) staining of PBL (A), of the lymph 
node HEV-specific B lymphoblastoid line LB-25 (B), and of the 
mucosal HEV-specific  line KCA (C). Indirect immunofluorescence 
was carried out as described in the Materials and Methods section. 
The shaded curves represent negative control staining (second 
stages only). 
cally or by  local  intramolecular alterations to  which  the 
mucosal HEV binding activity is uniquely susceptible). 
A Polyclonal anti-gp90 Blocks All Three 
Specificities of  Lymphocyte-HEV Binding 
To determine whether the Hermes-l-defined gpg0 might also 
be involved in recognition and binding to synovial HEV, a 
serum from mice hyperimmunized  with the isolated Hermes-I 
antigen  from  KCA was  employed.  This  polyclonal anti- 
Hermes-1  antigen (anti-gp90) serum is highly specific, im- 
munoprecipitating a diffuse 85-95-kD band from PBL (Fig. 
6,  lane A),  identical to that precipitated by Hermes-1  (lane 
E).  Furthermore,  the anti-gp90  serum displays the same 
staining pattern as Hermes-1  in immunohistologic studies of 
human tonsil and thymus (not shown). As shown in Fig. 6, 
lanes A and B, the 85-95-kd species precipitated by the poly- 
clonal antiserum is precleared by Hermes-l, indicating that 
Hermes-1 sees the entire set of  PBL surface molecules recog- 
nized by the polyclonal antiserum. Hermes-3 also preclears 
the polyclonal-defined molecules (lane  C),  and the poly- 
clonal antiserum preclears both the Hermes-1  and Hermes- 
3-defined species (lanes F and H, respectively). Thus both 
monoclonal antibodies and the polyclonal anti-gp90 serum 
define the same 85-95-kD glycoprotein class. 
As shown in Fig. 7, the polyclonal antiserum effectively 
blocks lymphocyte binding not only to mucosal, but also to 
lymph node and to synovial HEV. To exclude a nonspecific 
effect of surface-bound polyclonal antibodies, additional ex- 
periments were carried out with a rat antiserum against hu- 
man lymphocytes (ALS) produced by hyperimmunization 
with PBL and tonsillar lymphocytes: the ALS was absorbed 
with affinity-isolated  Hermes-1  antigen to remove anti-gp90 
reactivity. The absorbed serum no longer inhibited lympho- 
cyte binding to HEV (Fig. 7) even though it retained exten- 
sive reactivity with lymphocytes, staining PBL about 5-10 
times as brightly as the specific anti-gp90 serum by flow 
cytometry (both antisera used at a  1:200  dilution).  These 
findings demonstrate involvement of the gp90 in lymphocyte 
recognition of synovial as well as lymph node and mucosal 
HEV. 
Discussion 
We have used serologic approaches to define lymphocyte  sur- 
face molecules involved in  specific recognition of lymph 
node, mucosal, and synovial HEV in the human. We have 
shown (a) that an 85-95-kD glycoprotein antigen, defined by 
monoclonal antibody Hermes-l, is involved in each of these 
functionally independent adhesion events;  (b)  that organ- 
specifc receptor activities are discriminated functionally by 
two monoclonal antibodies that recognize this gp90 class, 
MEL-14,  which  specifically  inhibits  human  lyntphocyte 
binding to lymph node HEV,  and Hermes-3, which blocks 
only binding to  mucosal HEV;  and (c)  that a  polyclonal 
anti-gp90 serum, produced against highly purified Hermes-1 
antigen from a mucosal HEV-specific  cell line, inhibits all 
three classes of lymphocyte-HEV recognition. These find- 
ings demonstrate that a common molecular mechanism, as- 
sociated with the gp90 Hermes-1  antigen, is involved in at 
least three functionally independent recognition systems that 
direct lymphocyte homing. 
The  results  lend themselves to two possible  interpreta- 
tions. First, although the organ specificity of functional inhi- 
bition by monoclonal antibodies MEL-14 and Hermes-3 re- 
quires  that  the  antigenic  determinants they  recognize be 
intimately associated with the recognition event, it is possi- 
ble that the gp90 represents  an invariant molecule that is 
coexpressed and physically associated with functionally di- 
verse receptors yet to be identifed, or that constitutes one 
component of a  more complex composite receptor system 
(analogous perhaps to the CD3/T cell receptor complex). In 
this model, the inhibition of particular functional activities 
by monoclonal antibodies against distinct epitopes on the 
Hermes-1  antigen could represent selective interference with 
Figure 6. Immunoprecipitation analyses demonstrating the speci- 
ficity of the polyclonal anti-gp90 serum. The anti-gp90 serum, 
produced against  the Hermes-I antigen from cell line KCA, precipi- 
tates the same surface  molecules  defined  by Hermes-1 and Hermes-3. 
Lysates of iodinated PBL were immunoprecipitated  with the poly- 
clonal anti-gp90 (lanes A-D); Hermes-1 (lanes E and F); Hermes-3 
(lanes G and H); or a rat IgG2a negative control, 30G12 (lane I). 
Before specific immunoprecipitation, lysates were precleared by 
absorption four times with negative control antibody 281-2 (lanes 
A, E, G, and I); Hermes-1 (lane B); Hermes-3 (lane C); or the 
polyclonal anti-gp90 itself (lanes D, F, and H). The anti-gp90 im- 
munoprecipitate  (lane A) is completely absorbed by Hermes-1 (lane 
B), by Hermes-3 (lane C), and by itself (lane D). Conversely,  the 
Hermes-1 and Hermes-3 precipitates (lanes E and G, respectively) 
are removed by absorption with anti-gp90 (lanes F and H). 
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phocyte-HEV interaction.  PBL (2  ×  107 per sample) were incu- 
bated for 1 h with 200 Itl of anti-gp90, either undiluted (open bars; 
n  =  2) or at a 1:5 dilution (lightly  shaded bars; n  =  2,  except n 
=  3 on synovial HEV). Negative control incubations were carried 
out either in normal mouse serum (at the appropriate dilution),  or 
in 200 Ixl of normal mouse serum containing Hermes-1 at a final 
concentration  100 I.tg/ml; the binding of these control-treated cells 
defined relative adherence  ratio of unity  (dotted line).  The pre- 
coated lymphocytes were washed free of unbound antibody before 
assay. (Because the test antibodies were not present during the incu- 
bation of lymphocytes on frozen sections, in these experiments it 
was possible to use an internal standard population of FITC-labeled 
lymphocytes, mixed with each sample population before assay, to 
facilitate quantitative comparisons.  This modification of the assay 
has been described in detail [Jalkanen and Butcher, 1985].) To ex- 
clude a nonspecific role for cell surface-bound antibody, additional 
controls were carried out in the same manner with a rat antiserum 
produced  by hyperinununization  with  whole  human  peripheral 
blood and tonsillar lymphocytes. The darkly shaded bar illustrates 
inhibited binding ofPBL precoated with this ALS (1:8 to 1:20 dilu- 
tion, n --- 4). The control (dashed line) for ALS experiments is the 
binding of untreated PBL. Aliquots of the ALS were absorbed with 
the Hermes-1 antigen from tonsil cells, affinity isolated on Hermes- 
1-conjugated Sepharose beads, in order to remove antibodies reac- 
tive with the gp90. The gp90-absorbed  ALS no longer inhibited 
lymphocyte binding to HEV (hatched bar;  1:8 to 1:20 dilution,  n 
= 4). All results were confirmed on both human and mouse tissues. 
the association of the invariant gp90 with particular structur- 
ally distinct receptors; or selective steric hindrance of the 
function of particular associated receptors or components. 
Alternatively,  the  85-95-kD molecular class  defined by 
Hermes-1 could consist of a set of closely related but func- 
tionally  distinct  receptors  for  tissue-specific  HEV  deter- 
minants. This hypothesis is more readily reconciled with the 
ability of MEL-14 and Hermes-3 to discriminate function- 
ally between human lymphocyte binding activities for lymph 
node, mucosal, and synovial HEV; this functional discrimi- 
nation clearly requires that the gp90 class includes  mole- 
cules or molecular domains uniquely associated with each 
recognition event. 
A  corollary of this second hypothesis is that the gp90 on 
lymph node HEV-specific and mucosal HEV-specific cells, 
because they would be functionally independent members of 
the class, would necessarily be structurally and hence anti- 
genically distinct.  Previous  studies  in  murine  species  are 
consistent with this corollary, inasmuch as in these animal 
models putative homing receptors have been identified  by 
receptor subtype-specific monoclonal antibodies.  (Indeed, 
before the current studies, there was no direct evidence that 
common  or  related  molecular  elements  were  involved  in 
lymphocyte recognition  of different  HEV.)  For  example, 
monoclonal antibody MEL-14, which was useful for the cur- 
rent studies because of its reactivity with human lymphocyte 
gp90, defines a 90-kD mouse lymphocyte surface glycopro- 
tein involved in recognition of lymph node HEV, but does 
not  stain Peyer's patch HEV-specific cells  (Gallatin et al., 
1983).  Similarly, Chin et al. (1986) have described a mono- 
clonal antibody,  lB.2, that defines an 80-kD rat lymphocyte 
surface  molecule  involved in  binding  to  mucosal  but  not 
lymph node HEV. Like MEL-14 in the mouse, lB.2 appears 
to discriminate mucosal and lymph node receptor activities, 
in that a population of rat thoracic duct lymphocytes that are 
lymph node  HEV-specific is  lB.2  negative.  Thus  putative 
receptors for lymph node and mucosal endothelium are anti- 
genically distinct  in murine species.  In light of the  shared 
functional properties of the gp80-90 in the murine and hu- 
man studies, as well as the similarity in their apparent molec- 
ular masses and the reactivity of MEL-14 with both the hu- 
man and mouse glycoproteins, it seems likely that the murine 
gp80-90  and  the  Hermes-I-defined glycoprotein class are 
analogous. Taken together, these considerations offer signifi- 
cant  support  for the  hypothesis  that  the  gp90  defined  by 
Hermes-1 represent a family of homing receptors, with dis- 
tinct members mediating  recognition of lymph node,  mu- 
cosal, and synovial high endothelium. Direct demonstration 
of organ-specific binding of purified gp90 to high endothelial 
cells,  and/or correlation of specificity with detailed  struc- 
tural or sequence analyses, would be required to confirm this 
hypothesis. In addition, it will be important to develop anti- 
bodies capable of discriminating antigenically between func- 
tionally distinct receptors in the human. 
It should be mentioned that there are precedents for fami- 
lies  of closely related glycoprotein receptors with  diverse 
specificities, the most obvious being the immunoglobulins 
and the T cell receptors for antigen. Even a single amino acid 
within  the  ligand-binding  domain  of receptors  can  com- 
pletely alter ligand  specificity.  For example,  single amino 
acid  substitutions  at  residue  226  in  the  influenza  virus 
hemagglutinin result in striking alterations in ligand speci- 
ficity:  hemagglutinins  with  leucine  at  this  position  are 
specific  for NeuAc-alpha 2~6Gal-;  substitution  of gluta- 
mine results in loss of this activity, with specificity instead 
for NeuAc-alpha 2~3Gal-; substitution of methionine yields 
a  hemagglutinin  capable of interacting  with both of these 
structures (Rogers et al., 1983).  This example may be partic- 
ularly relevant because there is now considerable evidence 
to suggest that the mouse lymph node homing receptor is a 
carbohydrate-recognizing molecule (Stoolman et al.,  1984; 
Kieda and Monsigny, 1983; Yednock et al.,  1987). It will be 
important to determine whether the  Hermes-l-defined hu- 
man gp90 also behave as mammalian lectins. 
The present finding that at least three functionally distinct 
and  independently  regulated  cell-binding activities are as- 
sociated with a single apparent molecular class may have im- 
portant implications for studies of other cell-cell adhesion 
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sion molecules thought to be involved in a relatively general 
manner  in  neuron-neuron  (Edelman,  1983;  Rutishauser, 
1984;  Faissner et al., 1984),  neuron-glial cell (Grumet and 
Edelman,  1984),  or  epithelial  cell-cell  (Edelman,  1983; 
Yoshida and Takeichi,  1982;  Damsky et al.,  1983)  interac- 
tions might instead be composed of multiple functionally in- 
dependent  receptors capable,  at least theoretically,  of un- 
suspected fine specificity in vivo. In this context, it may be 
relevant  that several biologically  important  proteins previ- 
ously thought to be homogeneous,  for example protein ki- 
nase  C  and  the  GTP-binding  protein,  have  recently  been 
shown to be functionally diverse molecular families (Car- 
penter et al.,  1987; Bourne,  1986). 
Interestingly,  putative  mouse  lymphocyte  receptors  for 
lymph node HEV appear to be modified by covalent linkage 
to the polypeptide, ubiquitin  (Siegelman et al., 1986).  Ubi- 
quitin is an 8.5-kD polypeptide present conjugated to a variety 
of proteins in the nucleus and cytoplasm of most eukaryotic 
cells (Hershko, 1983).  At least part of the epitope recognized 
by MEL-14  appears  to be determined by the ubiquitin  se- 
quence (St. John et al., 1986), and it has been proposed that 
ubiquitination may play a role in receptor specificity or pro- 
cessing. The cross-reactivity of MEL-14 with the Hermes-1 
antigen, as demonstrated here, suggests that the human gp90 
may be ubiquitinated  as well. 
In studies to be reported elsewhere, we have  also found 
that the Hermes-1  antigen bears several N-linked glycans, in- 
corporated sulphate,  and considerable endoglycosidase F-re- 
sistant  sialic acid. The role of these post- or cotranslational 
modifications in the function and/or specificity of these mol- 
ecules remains to be determined. 
Although it is likely that the gp90 is essential for specific 
recognition and binding to HEV,  other cell surface mole- 
cules may  also play  a  role.  Rasmussen  et al.  (1985)  have 
reported a monoclonal antibody,  A.11, that inhibits  rat lym- 
phocyte binding to lymph node but not to mucosal HEV, and 
precipitates  several  molecular  species,  of Mr 40,  63,  and 
135 kD. Antibodies to certain epitopes of the LFA-1 molecu- 
lar complex also demonstrate partial  inhibition of lympho- 
cyte binding to lymph node and to mucosal HEV both in the 
mouse  (Hamann et al.,  manuscript submitted  for publica- 
tion)  and the  human  (N.  Wu,  unpublished  data)  systems. 
Thus several molecular species may operate, presumably in 
conjunction with the gp90, to effect lymphocyte recognition 
and adherence to high endothelial cells. 
In conclusion, we have demonstrated that antibodies able 
to interfere with particular  organ-specific lymphocyte-HEV 
recognition events bind to a common 85-95-kD glycoprotein 
antigen.  Further  studies must be carried out to determine 
whether this  gp90  represents  an  invariant  component  as- 
sociated with other surface elements conferring recognition 
specificity,  or  whether  it  instead  comprises  a  family  of 
closely related but functionally distinct receptors for HEV. 
The  observation  that  the  gp90  is  involved  in  lymphocyte 
binding to synovial HEV is of particular  interest, in that it 
raises  the possibility  of generating  monoclonal antibodies 
capable of specifically interfering with homing to inflamed 
joints,  for example in rheumatoid arthritis,  by immunizing 
with the Hermes-1  antigen from synovial HEV-binding  cells. 
It will be interesting  to determine whether, in addition to the 
three known homing specificities, the gp90 Hermes-1  anti- 
gen is involved in directing lymphocyte  traffic through many 
or all different organs in the body, and whether related glyco- 
proteins  play a role in other interacting cellular systems. 
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